HC Wainwright Reaffirms Neutral Rating for AnaptysBio (NASDAQ:ANAB)

AnaptysBio (NASDAQ:ANAB)‘s stock had its “neutral” rating restated by investment analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They currently have a $19.00 target price on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside of 18.31% from the company’s previous close.

Other analysts have also issued research reports about the stock. Guggenheim dropped their price target on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating on the stock in a research report on Thursday, December 12th. BTIG Research lowered AnaptysBio from a “buy” rating to a “neutral” rating in a report on Monday, December 2nd. UBS Group increased their target price on AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Wells Fargo & Company cut their price target on shares of AnaptysBio from $56.00 to $40.00 and set an “overweight” rating for the company in a report on Thursday, December 12th. Finally, Wedbush reaffirmed an “outperform” rating and set a $40.00 price objective on shares of AnaptysBio in a report on Monday. Four investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, AnaptysBio has an average rating of “Moderate Buy” and a consensus price target of $40.08.

AnaptysBio Price Performance

NASDAQ ANAB opened at $16.06 on Tuesday. AnaptysBio has a 1 year low of $12.51 and a 1 year high of $41.31. The company has a market capitalization of $488.71 million and a PE ratio of -2.64. The company has a fifty day moving average of $17.05 and a 200 day moving average of $26.77.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.58. The firm had revenue of $30.02 million for the quarter, compared to the consensus estimate of $7.92 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. Research analysts expect that AnaptysBio will post -6.08 earnings per share for the current year.

Insider Buying and Selling at AnaptysBio

In related news, Director Ecor1 Capital, Llc bought 65,184 shares of the business’s stock in a transaction on Monday, December 30th. The stock was acquired at an average cost of $12.92 per share, with a total value of $842,177.28. Following the purchase, the director now directly owns 7,860,180 shares of the company’s stock, valued at $101,553,525.60. The trade was a 0.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 33.70% of the stock is owned by insiders.

Institutional Investors Weigh In On AnaptysBio

Hedge funds have recently modified their holdings of the company. Frazier Life Sciences Management L.P. raised its stake in AnaptysBio by 2.0% during the third quarter. Frazier Life Sciences Management L.P. now owns 2,209,189 shares of the biotechnology company’s stock worth $74,008,000 after purchasing an additional 43,598 shares during the period. Point72 Asset Management L.P. raised its position in shares of AnaptysBio by 202.8% during the 3rd quarter. Point72 Asset Management L.P. now owns 54,200 shares of the biotechnology company’s stock valued at $1,816,000 after buying an additional 36,300 shares during the period. JPMorgan Chase & Co. lifted its holdings in AnaptysBio by 191.4% in the third quarter. JPMorgan Chase & Co. now owns 33,744 shares of the biotechnology company’s stock valued at $1,130,000 after acquiring an additional 22,164 shares during the last quarter. Victory Capital Management Inc. grew its position in AnaptysBio by 677.9% in the third quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock worth $7,948,000 after acquiring an additional 206,750 shares during the period. Finally, Assenagon Asset Management S.A. increased its stake in AnaptysBio by 55.1% during the third quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock worth $15,927,000 after acquiring an additional 168,813 shares during the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.